// App-Quantinova.ai

2047 : Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Researchers

Presenter

  • Gilles Salles

Principal Investigators

  • Aristeidis Chaidos

  • Pam McKay

  • Tycel J. Phillips

  • Sarit E Assouline

  • Connie Lee Batlevi

  • Philip Campbell

  • Vincent Ribrag

  • Gandhi Laurent Damaj

  • Michael Dickinson

  • Wojciech Jurczak

  • Maciej Kazmierczak

  • Stephen Opat

  • John A. Radford

  • Anna Schmitt

  • Jennifer Whalen

  • Anthony Hamlett

  • Beth Kamp

  • Deyaa Adib

  • Franck Morschhauser

Medical Centers

  • Lyon-Sud Hospital, Gastroenterology, Pierre-Benite, France

  • Service d'hématologie, Centre de Lutte Contre le Cancer Henri Becquerel, Rouen, France

  • Department of Haematology, Hammersmith Hospital, Imperial Healthcare NHS Trust, London, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Division of Hematology/Oncology, University of Michigan School of Medicine, Ann Arbor, MI

  • Division of Hematology,Sir Mortimer B. Davis-Jewish General Hospital, Department of Oncology, McGill University,Montreal, QC,Canada

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Barwon Health, University Hospital Geelong,Victoria,Australia

  • Gustave Roussy, Villejuif, France

  • Department of Hematology, University Hospital, School of Medicine, Caen, France

  • Dept. of Hematology, Peter MacCallum Cancer Center, Melbourne, Australia

  • UJCM, Krakow, Poland

  • Examen sp. z o.o,, Poznan, Poland

  • Clinical Haematology, Monash Health and Monash University, Clayton, Australia

  • The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

  • Institut Bergonie, Bordeaux, France

  • Data Management Department, Epizyme, Cambridge, MA

  • Epizyme, Inc., Cambridge, MA.

  • Department of Hematology, Centre Hospitalier regional universitaire, Lille, France

Locations

  • France

  • United Kingdom

  • United States

  • Canada

  • Australia

  • Poland

Companies

  • Epizyme, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • Enhancer of zeste homolog 2

Drug/Treatment

  • Tazemetostat

  • EZH2

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT01897571

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved